Blood test could spot hidden heart damage in preeclampsia
NCT ID NCT07463898
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks for proteins in the blood that might show early heart changes in women with preeclampsia, a serious pregnancy condition. Researchers will also use heart ultrasounds to see how the heart changes during pregnancy. The goal is to find ways to predict future heart problems in these women. About 172 pregnant women will participate, providing blood samples and having heart scans at two points during their pregnancy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to detect early heart strain in women with preeclampsia, helping prevent long-term heart problems.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not find clear markers, and results may not apply to all women.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR BIOMARKERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Abuja Teaching Hospital
Abuja, Nigeria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common blood pressure drug protect the placenta in Early-Onset preeclampsia?
- Can a phone app slash pregnancy care costs? new study aims to find out
- New blood test could spot dangerous pregnancy condition early
- Pregnancy study seeks links between insulin resistance and placental problems
- Could a simple hormone improve preeclampsia outcomes?
- Heart risk alert: troponin test may protect cancer patients on immunotherapy